vortioxetine versus placebo for treatment of major depressive disorder

Authors

masoud behzadifar tehran

hamidreza dehghan yazd

kourosh saki teharn

kourosh sayehmiri ilam

abstract

introduction: major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. approved by the fda in september 2013 for treatment of episodes of major depressive disorder, vortioxetine is one of the newer options available in this important area of therapeutics. materials and methods: a comprehensive literature search (pubmed, the cochrane library, scopus, crd and hta database in january 2015) was performed, containing controlled clinical trials that vortioxetine 10 mg/d versus placebo in adults with major depressive disorder. results: six controlled clinical trials were included in this meta-analysis. there was a significant difference between the vortioxetine 10 mg/d versus placebo in the montgomery–åsberg depression rating scale (madrs) (p value <0.00001). the results of pooled analysis for diarrhea, dry mouth, dizziness, headache and nausea were also significant (p value <0.00001). vortioxetine 10 mg/d versus placebo showed a significant difference for nausea, but no significant differences were observed for the other five adverse effects. conclusion: therapy with vortioxetine was significantly associated with reduction in depression symptoms from baseline compared to placebo.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Vortioxetine versus placebo for treatment of major depressive disorder

Introduction: Major depressive disorder is a common mental condition associated with substantial morbidity and economic burden. Approved by the FDA in September 2013 for treatment of episodes of major depressive disorder, Vortioxetine is one of the newer options available in this important area of therapeutics. Materials and methods: A comprehensive literature search (PubMed, the Cochrane libr...

full text

Vortioxetine: a New Treatment for Major Depressive Disorder.

INTRODUCTION Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD). This medication is a serotonin reuptake inhibitor that also has a number of other potentially relevant effects on serotoninergic receptors, which may differentiate the drug's effects from those of current first-line antidepressants, such as selective ser...

full text

A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults

The efficacy and safety of vortioxetine, an antidepressant approved for the treatment of adults with major depressive disorder (MDD), was studied in 11 randomized, double-blind, placebo-controlled trials of 6/8 weeks׳ treatment duration. An aggregated study-level meta-analysis was conducted to estimate the magnitude and dose-relationship of the clinical effect of approved doses of vortioxetine ...

full text

Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.

BACKGROUND Vortioxetine was approved by the U.S. Food and Drug Administration (FDA) in September 2013 for treating major depressive disorder (MDD). Thus far, a number of randomized, double-blind, placebo-controlled clinical trials (RCTs) of vortioxetine have been conducted in patients with MDD. We performed a meta-analysis to increase the statistical power of these studies and enhance our curre...

full text

Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.

INTRODUCTION Major depressive disorder (MDD), one of the most common disorders in medical practice and one of the leading causes of disability worldwide, is frequently comorbid with anxiety disorders. Vortioxetine (Lu AA21004) is a new antidepressant that combines a number of neurotransmitter reuptake and receptor effects that have been thought to predict efficacy as a treatment for depressive ...

full text

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder

VORTIOXETINE IS A NEW MULTIMODAL ACTION ANTIDEPRESSANT WITH TWO TYPES OF ACTION: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. It is an antagonist of the 5-HT3 and 5-HT7 receptors, a partial agonist of 5-HT1B, and an agonist of 5-HT1A. Its combined action on SERT and four subtypes of serotoninergic receptors increases the extracellular concent...

full text

My Resources

Save resource for easier access later


Journal title:
journal of basic research in medical sciences

جلد ۲، شماره ۳، صفحات ۳۱-۴۱

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023